Europe’s first blank check company focused on acquiring companies that make medicines for the biotech and pharmaceutical industry launched today, with plans to raise 150 million euros, Reuters reports.
The company, named eureKING, intends to list on Euronext Paris and has identified about 40 targets that manufacture biologics, cell and gene therapies, or live biotherapeutics (biological products that contains live organisms, such as bacteria to prevent, treat or cure disease).
Its targets are contract development and manufacturing organisations, which provide services to companies without the resources to do such work in-house. Read more.
